ProShare Advisors LLC Acquires 598 Shares of DaVita Inc. (NYSE:DVA)

ProShare Advisors LLC boosted its holdings in shares of DaVita Inc. (NYSE:DVA) by 9.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,817 shares of the company’s stock after buying an additional 598 shares during the quarter. ProShare Advisors LLC’s holdings in DaVita were worth $1,019,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. SBI Securities Co. Ltd. purchased a new position in DaVita during the fourth quarter valued at approximately $41,000. Coppell Advisory Solutions LLC lifted its holdings in DaVita by 50.0% during the fourth quarter. Coppell Advisory Solutions LLC now owns 300 shares of the company’s stock valued at $45,000 after purchasing an additional 100 shares in the last quarter. Canada Post Corp Registered Pension Plan purchased a new position in DaVita during the fourth quarter valued at approximately $55,000. Venturi Wealth Management LLC lifted its holdings in DaVita by 59.8% during the fourth quarter. Venturi Wealth Management LLC now owns 406 shares of the company’s stock valued at $61,000 after purchasing an additional 152 shares in the last quarter. Finally, Blue Trust Inc. lifted its holdings in DaVita by 39.7% during the fourth quarter. Blue Trust Inc. now owns 461 shares of the company’s stock valued at $76,000 after purchasing an additional 131 shares in the last quarter. 90.12% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have weighed in on DVA. Cowen reaffirmed a “hold” rating on shares of DaVita in a report on Tuesday, February 18th. Barclays lifted their price target on shares of DaVita from $164.00 to $169.00 and gave the company an “equal weight” rating in a report on Tuesday, February 18th. Truist Financial lowered their target price on shares of DaVita from $170.00 to $164.00 and set a “hold” rating on the stock in a report on Monday. Wall Street Zen raised shares of DaVita from a “hold” rating to a “buy” rating in a report on Friday, April 25th. Finally, Sanford C. Bernstein set a $184.00 target price on shares of DaVita in a report on Friday, February 21st. One research analyst has rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $164.50.

DaVita Price Performance

DVA stock opened at $138.55 on Friday. The company has a market capitalization of $10.46 billion, a PE ratio of 12.90, a price-to-earnings-growth ratio of 1.07 and a beta of 1.14. The company’s fifty day moving average price is $145.54 and its 200-day moving average price is $153.41. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26. DaVita Inc. has a one year low of $131.44 and a one year high of $179.60.

DaVita (NYSE:DVA) last released its quarterly earnings results on Monday, May 12th. The company reported $2.00 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.75 by $0.25. The company had revenue of $3.22 billion for the quarter, compared to the consensus estimate of $3.22 billion. DaVita had a net margin of 7.31% and a return on equity of 115.48%. DaVita’s revenue was up 5.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.26 earnings per share. On average, equities analysts anticipate that DaVita Inc. will post 10.76 EPS for the current fiscal year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.